Ann: Investor Presentation, 14 March 2023, page-72

Hottodd,

Your last line - think about that for a minute.

Are you perhaps suggesting or prompting the thought/discussion that it could have broader applications for weight management and weight loss in the future, perhaps even for assistance in treating diabetes??

I could be way off base but if that is what you are implying then I think we are due for a total rethink of 2591.

I am not convinced that other indications Concussion / TBI, ASD, Parkinsons, Dementia are off the table for 2591. Whether that be as a stand alone treatment or a complimentary treatment, so for me, SP predictions in the sub $100 range don't even begin to ascribe proper value to us.

If however, it possibly does have broader applications than just neurological conditions then I think this has the hallmarks of becoming the most expensive stock on the ASX - and by many multiples of the current holder of that title.

Appreciate that is a lot of "ifs" and Neuren may not exist before all that comes to pass and there are plenty of caveats but Wilson's value us at $100 per share fully de-risked. We are many multiples of that if the treatment profile of the drug (fast loss, insulin normalisation) can be obtained off label.

I believe that we are sitting on something truly special - something that I think will go down in history.

Some people will call me deluded but I just have a gut feeling.